Skip to main content

MPS Aims For ₹1000 Crore Revenue By FY27

MPS Limited has outlined a clear path to cross ₹1,000 crore in revenue by FY27. The company's operational trajectory is strongly supported by its recent Q1 FY27 performance, which saw consolidated net profits jump 42.99% YoY to ₹50.39 crore. Strategic expansions, including a new Singapore subsidiary and AI-first healthcare integration, reinforce this growth outlook.

Author Image
Sahi Markets
Published: 22 Jul 2026, 02:00 PM IST (1 hour ago)
Last Updated: 22 Jul 2026, 02:00 PM IST (1 hour ago)
2 min read
Reviewed by Arpit Seth

Market snapshot: MPS Limited has reiterated its operational roadmap, targeting an implied organic top-line revenue of ₹900 crore to ₹1,000 crore by FY27. This milestone is closely linked with the company's reiterated FY27 EBITDA guidance of over ₹300 crore, supported by strong Q1 FY27 results where revenues grew by over 20% year-on-year.

Data Snapshot

  • Consolidated Q1 FY27 revenue from operations increased to ₹224.24 crore, representing ≈20.38% YoY growth (derived: ₹224.24 crore vs ₹186.28 crore).
  • Consolidated net profit for Q1 FY27 reached ₹50.39 crore, growing ≈42.99% YoY (derived: ₹50.39 crore vs ₹35.24 crore).
  • Consolidated EBITDA margins expanded to 34.32% in Q1 FY27 from 27.04% in the corresponding quarter of the previous fiscal year.

What's Changed

  • Operating margins improved significantly, with EBITDA margins jumping from 27.04% in Q1 FY26 to 34.32% in Q1 FY27, showcasing high operational leverage from automation.
  • Geographic expansion has accelerated with the Board's approval to incorporate a wholly-owned subsidiary in Singapore with an investment of up to ₹1 crore.

Key Takeaways

  • Strong operational leverage in Q1 FY27 enabled net profit to grow at double the rate of revenue expansion.
  • Reiteration of the FY27 EBITDA target of over ₹300 crore signals strong visibility into high-margin recurring corporate and publishing contracts.
  • The setup of a Singapore subsidiary provides a global launchpad for cross-border synergies and potential inorganic acquisitions.
  • Papinani Radha Rani's appointment as Chief Risk Officer strengthens the risk management framework amid rising international operations.

SAHI Perspective

MPS's robust margins prove that its AI-first workflow transition is paying off. Achieving the upper band of the ₹1,000 crore revenue target by FY27 looks highly achievable, especially as the company's second half historically outpaces its first half. This operational efficiency keeps the company well-aligned with its longer-term 'Vision 2027' revenue target of ₹1,500 crore by FY28.

Market Implications

Stellar Q1 FY27 execution and forward guidance have driven strong investor interest, with the stock rallying 19% to hit a 52-week high of ₹2,539.80 on July 22, 2026. Ongoing progression toward the ₹300 crore EBITDA guidance will serve as a key valuation catalyst.

Trading Signals

Market Bias: Bullish

Supported by a 42.99% YoY increase in Q1 net profit to ₹50.39 crore and EBITDA margins at a robust 34.32%, the financial momentum strongly backs the company's near-term targets.

Overweight: Publishing, eLearning, Corporate Learning

Trigger Factors:

  • Consistent margin sustenance above 33% in subsequent quarters.
  • Operational scaling and commercialization under the new Singapore subsidiary.
  • Smooth integration of the recently acquired Unbound Medicine clinical platform.

Time Horizon: Near-term (0-3 months)

Industry Context

The global knowledge and publishing solutions industry is currently reorganizing around artificial intelligence and subscription-based digital learning assets. MPS's strategic shift to prioritize high-margin AI platforms and recurring B2B subscriptions is helping it capture market share ahead of legacy, print-heavy competitors.

Key Risks to Watch

  • Quarterly performance remains subject to seasonality, particularly within the eLearning and publishing divisions.
  • Slight integration risks could arise from new international business pipelines and regulatory compliance under FEMA guidelines.

Recent Developments

In February 2026, MPS completed the strategic acquisition of US-based healthcare AI platform Unbound Medicine Inc. for $15.18 million. Following this, on July 21, 2026, the Board approved the incorporation of a wholly-owned subsidiary in Singapore with an investment of up to ₹1 crore.

Closing Insight

MPS is demonstrating that scalable, technology-enabled business models can successfully offset seasonal headwinds. With Q1 landing ahead of a straight-line path, the ₹1,000 crore revenue milestone is firmly within reach.

High Performance Trading with SAHI.

Disclaimer: This news section may include AI-generated or AI-assisted news, summaries, drafts, or insights. All content is subject to human review before publication. While we aim for accuracy, readers should independently verify information before relying on it.

Trade This Move With Sahi

Frequently Asked Questions (FAQs)

All topics